Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
作者:
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);药物替代(Drug Substitution);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);男(雄)性(Male);中年人(Middle Aged);外周血管疾病(Peripheral Vascular Diseases);胸腔积液(Pleural Effusion);蛋白激酶抑制剂(Protein Kinase Inhibitors);嘧啶类(Pyrimidines);再治疗(Retreatment);回顾性研究(Retrospective Studies);治疗失败(Treatment Failure);治疗结果(Treatment Outcome);青年人(Young Adult)
DOI
10.3109/10428194.2014.994205
PMID
25563556
发布时间
2022-01-14
- 浏览30

Leukemia & lymphoma
2309-14页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文